1.Date of occurrence of the event:2022/06/01
2.Company name:Microbio Co.,LTD.
3.Relationship to the Company (please enter ”head office” or
  ”subsidiaries”):Head office
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:The Company has been informed by the patent agency
that the new drug: MS-20 has been granted a Republic of China patent titled
“COMBINED CANCER THERAPY WITH IMMUNE CHECKPOINT MODULATORS AND FERMENTATION
PRODUCTS BY SYMBIOTIC MICROBIOTA” under patent number I762473.
6.Countermeasures:NA
7.Any other matters that need to be specified:
(1)The patents from the U.S., the Republic of China, Japan, the People's
   Republicof China, the Hong Kong Special Administrative Region, Europe,
   Korea,Indonesia, India, Canada, Singapore, Malaysia, United Arab
   Emirates and Brazil have been subsequently granted on the new drug,
   Chemoyoung (MS-20).
(2)This patent presents a combination therapy with Chemoyoung (MS-20) and
   anti-PD1 antibody to enhance the anti-cancer efficacy of immune checkpoint
   modulators.